|Awarded On||February 19, 2020|
|Title||Targeting MEK in EGFR-Amplified Glioblastoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||John de Groot|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
The median survival for patients with recurrent glioblastoma is six to nine months highlighting the need for better therapeutic strategies for this deadly disease. The revolution in cancer genomics has identified multiple amplification events as potential targets for therapeutic intervention in many cancers including glioblastoma. Multiple factors such as incorrect patient selection, inadequate drug delivery across the blood brain barrier, acquired resistance and drug-target heterogeneity may all lead to clinical failure of targeted therapies. Through an unbiased high-throughput screen utilizing our glioma stem-like cells (GSCs) we discovered that glioblastoma cells harboring focal EGFR ampl...